# Impact Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/impact-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.impacttherapeutics.com
- Total disclosed funding: $145M
- Latest round: Series D (Apr 19, 2024)
- Investors on record: 22

## About

Based in Nanjing, China and founded in 2009, IMPACT Therapeutics, Inc., dba Impact Therapeutic, is a drug developer dedicated to developing new targeted anti-cancer drugs with independent intellectual property rights. It has a sub-branch office in Shanghai. The CEO of the company, Dr. Sui Xiong Cai graduated from the University of Oregon. The CSO of the company, Dr. Ye Edward Tian graduated from the Michigan State University and has new drug R&D experience in pharmaceutical companies and biotechnology companies. In May 2026,?Impact Therapeutics?raised?HKD 843.7 million?in an IPO, selling?41.98 million shares?at?HKD 20.1 per share at Hong Kong Stock Exchange, under the ticker "7630".

The company focuses on synthetic lethal mechanisms of action that can kill cancer cells with certain mutations, such as defects in DNA damage repair. It mainly develops DNA damage response (DDR) product portfolio. The company's pipeline includes PARP inhibitor (Senaparib/IMP4297), Wee1 inhibitor (IMP7068), and multiple other DDR target inhibitors. PARP inhibitors are used in ovarian cancer, prostate cancer, small cell lung cancer and other diseases.

The company generates revenue by developing and delivering drugs to treat cancer and other life-threatening diseases.

## Funding rounds

- Series D, Apr 19, 2024, $55M — Lilly Asia Ventures, GTJA Investment Group, Xiamen C&D Emerging Industry Equity Investment, Kingray Capital, Yangzhou International Finance Investment, Guyu Nange
- Series D, Mar 14, 2022 — Lilly Asia Ventures, Yuexiu Industrial Investment Funds Management, China Summit Capital, Dingxin Capital, CCB Investment Funds Management, Xiamen C&D Emerging Industry Equity Investment, Exome Asset Management, Bestride
- Series C, Nov 30, 2020, $50M — Lilly Asia Ventures, Zhejiang Ausun Pharmaceutical Co., Ltd, China Summit Capital, Shenzhen Capital Real Estate Fund, Shanghai Junshi Biosciences Co., Ltd., Ruihe Xingye Asset
- Series C, Aug 3, 2018, $30M — Lilly Asia Ventures, Decheng Capital
- Series B, Dec 1, 2015, $10M — Lilly Asia Ventures, Yuexiu Industrial Investment Funds Management, YuanBio Venture, Haibang Venture, Asia Summit Capital
- Series A, Jul 8, 2014 — Lilly Asia Ventures, Cenova Ventures, 6 Dimensions Capital

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B, Series C, Series D
- Cenova Ventures (https://capitalatlas.ai/funds/cenova-ventures) — Series A
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A
- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Series B, Series D
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B
- Haibang Venture — Series B
- Asia Summit Capital — Series B
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series C
- Zhejiang Ausun Pharmaceutical Co., Ltd — Series C
- China Summit Capital (https://capitalatlas.ai/funds/china-summit-capital) — Series C, Series D
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series C
- Shanghai Junshi Biosciences Co., Ltd. — Series C
- Ruihe Xingye Asset (https://capitalatlas.ai/funds/ruihe-xingye-asset) — Series C
- Dingxin Capital — Series D
- CCB Investment Funds Management (https://capitalatlas.ai/funds/ccb-investment-funds-management) — Series D
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series D
- Exome Asset Management — Series D
- Bestride — Series D
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series D
- Kingray Capital (https://capitalatlas.ai/funds/kingray-capital) — Series D
- Yangzhou International Finance Investment — Series D
- Guyu Nange — Series D